Update on topical carbonic anhydrase inhibitors

Current Opinion in Ophthalmology

Volumn 12, Issue 2, 2001, Pages 88-93

  Herkel, Ulrike ^a   Pfeiffer, Norbert ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BRINZOLAMIDE; CARBONATE DEHYDRATASE INHIBITOR; DORZOLAMIDE; LATANOPROST; TIMOLOL;

AQUEOUS HUMOR; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SELECTIVITY; EYE BLOOD FLOW; GLAUCOMA; HUMAN; INTRAOCULAR PRESSURE; PH; PRIORITY JOURNAL; REVIEW;

ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; BLOOD FLOW VELOCITY; CARBONIC ANHYDRASE INHIBITORS; CARBONIC ANHYDRASES; DOSE-RESPONSE RELATIONSHIP, DRUG; EYE; GLAUCOMA; HUMANS; INTRAOCULAR PRESSURE; OPHTHALMIC SOLUTIONS; PROSTAGLANDINS F, SYNTHETIC; SULFONAMIDES; THIAZINES; THIOPHENES;

EID: 0035078549     PISSN: 10408738     EISSN: None     Source Type: Journal    
DOI: 10.1097/00055735-200104000-00002     Document Type: Review

References (50)

1. Dorzolamide: Development and clinical application of a topical carbonic anhydrase inhibitor
2. Topical carbonic anhydrase inhibitors
3. Lokaler karboanhydrasehemmer dorzolamide
4. Preclinical overview of brinzolamide
5. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes
6. Dose-response evaluation of the ocular hypotensive effect of brinzolamide ophthalmic suspension (Azopt)
7. The long-term safety and efficacy of brinzolamide 1.0% (Azopt) in patients with primary open-angle glaucoma or ocular hypertension
8. The efficacy and safety of brinzolamide 1% ophthalmic suspension (Azopt) as a primary therapy in patients with open-angle glaucoma or ocular hypertension
9. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension
10. Brimonidine 0.2% versus dorzolamide 2% each given three times daily to reduce intraocular pressure
11. A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: A 3 month, randomised study
12. Effect of timolol, latanoprost, and dorzolamide on circadian lOP in glaucoma or ocular hypertension
13. Adjunctive therapy with brinzolamide 1% ophthalmic suspension (Azopt) in patients with open-angle glaucoma or ocular hypertension maintained on timolol therapy
14. Comparison of the efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects
15. A double-masked, randomized 1-year study comparing dorzolamide (Trusopt), timolol, and betaxolol
16. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical beta-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension
17. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension. A 3-month randomised study
18. Additive effect of latanoprost to the combination of timolol and dorzolamide
19. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with beta-blockers in glaucoma
20. The dorzolamide/timolol combination versus timolol plus pilocarpine: Patient preference and impact on daily life
21. Ocular Comfort of Brinzolamide 1.0% Ophthalmic Suspension Compared With Dorzolamide 2.0% Ophthalmic Solution. Results From Two Multicenter Comfort Studies
22. The preclinical pharmacology of dorzolamide hydrochloride, a topical carbonic anhydrase inhibitor
23. Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor
24. Central corneal thickness in normal, glaucomatous, and ocular hypertensive eyes
25. Irreversible corneal decompensation in patients treated with topical dorzolamide
26. Irreversible corneal decompensation in patients treated with topical dorzolamide
27. Effect of dorzolamide on corneal endothelial function in normal human eyes
28. Corneal endothelial cell density in glaucoma
29. Dorzolamide and corneal recovery from edema in patients with glaucoma or ocular hypertension
30. Human lens carbonic anhydrases. Purification and properties
31. Human carbonic anhydrases and carbonic anhydrase deficiencies
32. Sterile mucopurulent conjunctivitis associated with the use of dorzolamide eyedrops
33. Nephrolithiasis with dorzolamide
34. Glaucoma and vasospasm
35. Hypertension, perfusion pressure, and primary open-angle glaucoma. A population-based assessment
36. Ambulatory blood pressure monitoring in glaucoma. The nocturnal dip
37. Peripapillary focal retinal arteriolar narrowing in open angle glaucoma
38. Relationship between ocular perfusion pressure and retrobulbar blood flow in patients with glaucoma with progressive damage
39. The effect of acetazolamide on the retinal circulation
40. Effect of topical dorzolamide on tissue circulation in the rabbit optic nerve head
41. Effect of topical dorzolamide on optic nerve head blood flow
42. Dorzolamide effect on ocular blood flow
43. Ocular pulse amplitude, intraocular pressure and beta blocker/carbonic anhydrase inhibition in combined therapy of primary open-angle glaucoma
44. Dorzolamide, visual function and ocular hemodynamics in normal-tension glaucoma
45. A comparative study of betaxolol and dorzolamide effect on ocular circulation in normal-tension glaucoma patients
46. The retinal blood flow in diabetes
47. Optic nerve oxygen tension in pigs and the effect of carbonic anhydrase inhibitors
48. Topical dorzolamide increases optic nerve oxygen tension in the pig
49. The European Glaucoma Prevention Study: Objectives and methods